Smartwatch and app join fight against metastatic breast cancer

NCT ID NCT07371585

Recruiting now Disease control Sponsor: SOLTI Breast Cancer Research Group Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the drug trastuzumab deruxtecan (T-DXd) as a first treatment for people with HER2-positive breast cancer that has spread. About 300 participants will take the drug and use digital tools like a smartwatch and pulse oximeter to catch side effects early. The goal is to see if this approach helps control the cancer and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (T-DXd)
What this could lead to: If successful, this could confirm T-DXd as an effective first-line treatment for HER2-positive metastatic breast cancer, potentially improving how long patients live without needing other therapies.
What could go wrong: This is a Phase 2, single-arm study without a comparison group, so results may not prove superiority over current standards. Side effects like lung inflammation (ILD) are a known risk with T-DXd.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER STAGE IV

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Centro Hospitalario Universitario de Santiago (CHUS)
NOT_YET_RECRUITING

Santiago de Compostela, Spain
Complexo Hospitalario Universitario A Coruna
NOT_YET_RECRUITING

A Coruña, Spain
Gustave Roussy
NOT_YET_RECRUITING

Villejuif, 94805, France
Hospital 12 Octubre
RECRUITING

Madrid, Spain
Hospital Clinico Universitario de Valencia
NOT_YET_RECRUITING

Valencia, Spain

Contact Email: •••••@•••••
Hospital Clínic de Barcelona
RECRUITING

Barcelona, Spain
Hospital Clínico Universitario de Valladolid
RECRUITING

Valladolid, Spain

Contact Email: •••••@•••••
Hospital General Universitario Dr. Balmis
RECRUITING

Alicante, Spain
Hospital Regional Universitario de Málaga
RECRUITING

Málaga, Spain
Hospital Sant Joan de Reus
RECRUITING

Reus, Spain

Contact Email: •••••@•••••
Hospital Son Espases
RECRUITING

Palma de Mallorca, Spain
Hospital Universitari Arnau De Vilanova De Lleida
NOT_YET_RECRUITING

Lleida, Spain
Hospital Universitari Vall d'Hebrón
RECRUITING

Barcelona, Barcelona, 08035, Spain

Contact Email: •••••@•••••
Hospital Universitario Clínico San Cecilio
RECRUITING

Granada, Spain
Hospital Universitario De Fuenlabrada
NOT_YET_RECRUITING

Madrid, Spain

Contact Email: •••••@•••••
Hospital Universitario Leon
RECRUITING

León, Spain
Hospital Universitario Lozano Blesa
RECRUITING

Zaragoza, Spain
Hospital Universitario Virgen Del Rocío
NOT_YET_RECRUITING

Seville, Spain
Hospital Universitario de Badajoz
RECRUITING

Badajoz, Spain

Contact Email: •••••@•••••
Hospital Universitario de Basurto
NOT_YET_RECRUITING

Bilbao, Spain
Hospital Universitario de Canarias
NOT_YET_RECRUITING

Santa Cruz de Tenerife, Spain

Contact Email: •••••@•••••
Hospital Universitario de Valdecilla
NOT_YET_RECRUITING

Santander, Spain
Hospital Universitaro Ramón y Cajal
NOT_YET_RECRUITING

Madrid, Spain
Institut Català d'Oncologia (ICO) Girona
NOT_YET_RECRUITING

Girona, Spain
Institut Català d'Oncologia (ICO) Hospitalet
NOT_YET_RECRUITING

L'Hospitalet de Llobregat, Spain
Instituto Valenciano de Oncologia (IVO)
NOT_YET_RECRUITING

Valencia, Spain
Klinikum der Universitaet Muenchen AöR
NOT_YET_RECRUITING

München, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.